Evrysdi
E561095
Evrysdi is an oral prescription medication used to treat spinal muscular atrophy (SMA) by increasing production of the survival motor neuron (SMN) protein.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Evrysdi canonical | 1 |
Statements (50)
| Predicate | Object |
|---|---|
| instanceOf |
disease-modifying therapy
ⓘ
orphan drug ⓘ pharmaceutical drug ⓘ prescription medicine ⓘ |
| affectsBiologicalProcess | RNA splicing ⓘ |
| affectsProtein | survival motor neuron protein NERFINISHED ⓘ |
| belongsToTherapeuticArea |
neurology
ⓘ
rare diseases ⓘ |
| hasActiveIngredient | risdiplam NERFINISHED ⓘ |
| hasApprovalYear | 2020 ⓘ |
| hasATCCode | M09AX10 ⓘ |
| hasBlackBoxWarning | none ⓘ |
| hasCommonAdverseEffect |
arthralgia
ⓘ
diarrhea ⓘ fever ⓘ headache ⓘ nausea ⓘ rash ⓘ ulceration of the mouth ⓘ upper respiratory tract infection ⓘ urinary tract infection ⓘ |
| hasDeveloper |
Genentech
NERFINISHED
ⓘ
PTC Therapeutics NERFINISHED ⓘ Roche NERFINISHED ⓘ SMA Foundation NERFINISHED ⓘ |
| hasDosingBasis | patient body weight ⓘ |
| hasDosingPopulation |
adults
ⓘ
children ⓘ infants ⓘ |
| hasGenericName | risdiplam ⓘ |
| hasIndication | treatment of spinal muscular atrophy in patients 2 months of age and older ⓘ |
| hasManufacturer | Genentech NERFINISHED ⓘ |
| hasMechanismOfAction |
SMN2 pre-mRNA splicing modifier
ⓘ
increases production of functional SMN protein ⓘ |
| hasPregnancyCategory | can cause fetal harm based on animal data ⓘ |
| hasRegulatoryStatus | prescription only ⓘ |
| hasRouteOfAdministration | oral ⓘ |
| hasStorageCondition |
refrigerate before reconstitution
ⓘ
store at room temperature after reconstitution for limited time ⓘ |
| hasTradeNameOwner | Genentech NERFINISHED ⓘ |
| isAdministered |
by mouth
ⓘ
once daily ⓘ |
| isApprovedBy | U.S. Food and Drug Administration NERFINISHED ⓘ |
| isDosageForm | oral solution ⓘ |
| isFirstInClass | first oral SMN2 splicing modifier approved for SMA ⓘ |
| isTakenWith | food or liquid ⓘ |
| isUsedIn | long-term treatment of spinal muscular atrophy ⓘ |
| targets | SMN2 pre-mRNA ⓘ |
| treats |
5q-associated spinal muscular atrophy
ⓘ
spinal muscular atrophy ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.